RanBPM inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of RanBPM (Ran-binding protein in the microtubule-organizing center), a multifunctional scaffold protein involved in several cellular processes, including signal transduction, cytoskeletal organization, and transcriptional regulation. RanBPM interacts with a variety of proteins through its multiple domains, including its SPRY domain, which mediates protein-protein interactions, and its LisH domain, involved in dimerization and cytoskeletal dynamics. As a scaffold protein, RanBPM plays a critical role in assembling protein complexes that regulate processes such as cell migration, apoptosis, and transcriptional control. Inhibitors of RanBPM act by binding to these critical domains, thereby disrupting its ability to mediate protein-protein interactions and impairing the downstream signaling pathways that rely on RanBPM scaffolding functions.
Inhibition of RanBPM leads to disruptions in the cellular processes it regulates, particularly those involving cytoskeletal integrity, intracellular trafficking, and signal transduction. By blocking RanBPM's interactions with key proteins, these inhibitors prevent the assembly of essential multiprotein complexes, thereby affecting cellular functions such as cell adhesion, migration, and response to external stimuli. Researchers use RanBPM inhibitors to explore the protein's role in various signaling pathways, as well as to investigate how it contributes to the organization of protein complexes within cells. These inhibitors provide valuable insights into the molecular mechanisms by which RanBPM influences diverse cellular processes, offering a clearer understanding of how scaffold proteins contribute to maintaining cellular architecture and transmitting signals from the cell surface to the nucleus. Additionally, RanBPM inhibitors help to elucidate the protein's broader role in coordinating signaling networks and its involvement in processes that regulate cellular behavior and structural organization.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
May lead to the demethylation of CpG islands within the RanBPM promoter, potentially resulting in the transcriptional silencing of the gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Could enhance histone acetylation, thereby altering the accessibility of transcriptional machinery to the RanBPM gene and leading to decreased expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
May directly bind to DNA and obstruct the elongation phase of RNA polymerase during RanBPM gene transcription, leading to a reduction in mRNA synthesis. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
By stabilizing the DNA-topoisomerase II complex, it could interfere with the transcriptional machinery's ability to properly transcribe the RanBPM gene. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Might selectively bind to the RanBPM gene promoter's GC-rich sequences, obstructing the necessary transcription factors and leading to decreased gene expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Could disrupt lysosomal degradation pathways, leading to the accumulation of transcriptional repressors that specifically target and downregulate RanBPM expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Could competitively inhibit BET bromodomains, leading to the displacement of transcriptional regulators from chromatin and subsequent downregulation of RanBPM transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
Could induce DNA hypomethylation and promote the binding of repressive transcription factors to the RanBPM promoter, culminating in decreased gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
This HDAC inhibitor could lead to hyperacetylation of histones associated with the RanBPM gene, resulting in the recruitment of transcriptional co-repressors and diminished expression. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Could interfere with estrogen receptor-mediated transcriptional activation of the RanBPM gene, leading to a reduction in its expression levels in certain breast tissue cells. | ||||||